drugset / Trial / NCT02318784
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
Timeline
- Start
- 2015-07-15
- Primary completion
- 2021-05-15
- Completion
- 2021-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |